Genomic test predicts PCa outcomes in African-American men
The Decipher genomic classifier is as effective in predicting prostate cancer metastasis and mortality in African-American men as it is in Caucasian men, according to new study findings reported by Stephen Freedland, MD, of Cedars-Sinai Medical Center, Los Angeles.
The Decipher genomic classifier is as effective in predicting prostate cancer metastasis and mortality in African-American men as it is in Caucasian men, according to new study findings reported by Stephen Freedland, MD, of Cedars-Sinai Medical Center, Los Angeles.
The data give clinicians confidence that the test can be used in African-American men, Dr. Freedland said in this Urology Times video interview at the Genitourinary Cancers Symposium in San Francisco. “It’s OK to start using this test in black men tomorrow,” he said.
Dr. Freedland discusses the rationale for the study, its key findings, and clinical implications.
Dr. Freedland disclosed the employment of an immediate family member with Genomic Health, stock/other ownership interests with Armune BioScience, and advisory roles with pharmaceutical and diagnostics companies. Three of the study co-authors are employees of Decipher Biosciences (formerly GenomeDx).
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
